Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine

Junya Hashizume, a Kyohei Shiojiri, a Emi Ryu, a,b Yuki Kawauchi, a Kyoko Hasegawa, a Nozomi Ezaki, a Haruna Yamashita, a,b,c Koji Ishii, a,b,c Hitomi Harasawa, a Tadahiro Nakamura, a Hitoshi Sasaki, a and Yukinobu Kodama* a,b

*Department of Hospital Pharmacy, Nagasaki University Hospital; 1–7–1 Sakamoto, Nagasaki 852–8501, Japan; b Nagasaki University Palliative Care Center; 1–7–1 Sakamoto, Nagasaki 852–8501, Japan; and c Department of Anesthesiology, Nagasaki University Hospital; 1–7–1 Sakamoto, Nagasaki 852–8501, Japan.

Received March 5, 2021; accepted May 21, 2021

Naldemedine (NAL), a peripherally acting µ-opioid receptor antagonist, is effective for opioid-induced constipation (OIC). However, diarrhea is the most common adverse event. We investigated the incidence of NAL-induced diarrhea in the administration of NAL-induced diarrhea among patients who started NAL at Nagasaki University Hospital between June 2017 and March 2019. Predictors of NAL-induced diarrhea were analyzed using a multivariate logistic regression model. Two hundred and forty-two patients were included in the present study, and NAL-induced diarrhea was observed in 17.8% (43 patients). The results of multiple logistic regression analyses identified the administration of opioid analgesics for 8 d or before the initiation of NAL (odds ratio (OR): 2.20, 95% confidence interval (95% CI): 1.04–4.64, p = 0.039), the combination of a laxative (OR: 2.22, 95% CI: 1.03–4.81, p = 0.042), and the combination of CYP3A4 inhibitors (strong/moderate) (OR: 2.80, 95% CI: 1.02–7.67, p = 0.045) as risk factors. Therefore, the development of diarrhea needs to be considered in patients with these risk factors. Furthermore, diarrhea may be controlled by the initiation of NAL within 7 d of opioid analgesics and, where possible, the discontinuation of or change in the combination of moderate or strong CYP3A4 inhibitors.

Key words naldemedine; diarrhea; predictive factor; opioid analgesic; laxative; CYP3A4 inhibitor

INTRODUCTION

Opioid analgesics exert excellent effects on cancer pain or chronic pain by stimulating µ-opioid receptors in the central nervous system. However, major adverse events include nausea/vomiting, constipation, and drowsiness. Opioid-induced constipation (OIC) has been reported to occur in >40% of patients treated with opioid analgesics.1–4) OIC is defined as changes from baseline bowel habits and defecation patterns, such as reduced bowel frequency, the development or worsening of straining, a feeling of incomplete defecation, or an awareness of patient distress associated with bowel habits after the initiation of opioids.5) OIC is not tolerated as well as the other adverse events of nausea/vomiting and drowsiness, and OIC-induced abdominal discomfort and defecation symptoms persist throughout the administration of opioids.6) OIC deteriorates QOL, such as vitality, physical functioning, mental state, mental health, general health, and social functioning. Adherence to opioid analgesics is also poor, which, in turn, results in inadequate pain management.7) Therefore, the prevention and/or treatment of OIC are important.

The guidelines of the European Association for Palliative Care (EAPC),8) European Society for Medical Oncology (ESMO),9) National Comprehensive Cancer Network (NCCN),10) and Japanese Society for Palliative Medicine11) recommend osmotic and colonic laxatives as first-line treatments for OIC. Peripheral µ-opioid receptor antagonists (PAMORAs) are considered when OIC is refractory to laxatives. Although PAMORAs are effective against OIC, they cause gastrointestinal toxicity, such as diarrhea, abdominal pain, nausea, and vomiting. A meta-analysis revealed that the risk ratio for diarrhea was 2.07.12)

All currently available PAMORAs, including naldemedine (NAL),13) methylnaltrexone,14) alvimopan,15) naloxone,16) and oral naloxone,17) are effective treatments for OIC. A recent network meta-analysis showed that NAL and naloxone were the most effective for OIC.18) NAL is the only PAMORA that is approved in Japan and is widely used for cancer or non-cancer patients with OIC. In a phase III randomized placebo-controlled trial, the frequency of spontaneous bowel movements was significantly increased in cancer patients receiving NAL.19) Adverse events occurred in 44.3% of patients, with the most common adverse event being diarrhea (19.6%). The frequency of NAL-induced diarrhea was the highest on the first day of administration and gradually decreased after the second day.20) If the incidence of diarrhea can be predicted, the safer administration of NAL may be possible. We previously reported that NAL-induced diarrhea significantly increased when opioid analgesics were administered for more than 8 d prior to the initiation of NAL.21) Similar results also have been reported by other groups.21,22)

On the other hand, NAL is mainly metabolized by CYP3A4. The concomitant use of CYP3A4 inhibitor and NAL increase blood concentration of NAL.23) In addition, the incidence of NAL-induced diarrhea was higher in patients receiving 0.4 mg/d than in those receiving the approved dose of 0.2 mg/d, in phase II trial.24,25) Therefore, CYP3A4 inhibitors may affect the incidence of NAL-induced diarrhea as a result of increasing blood levels of NAL. However, there are no reports the association between NAL-induced diarrhea and the
concomitant use of CYP3A4 inhibitor. In the previous study, we reported that the duration of opioid analgesics was the predictive factor of NAL-induced diarrhea. Then, we extended the study period to increase the number of patients in order to improve the reliability of the information compared to previous reports, and conducted retrospective study including the presence or absence of concomitant use of CYP3A4 inhibitors. As a result, we have found for the first time that the combinations of CYP3A4 inhibitors or laxatives are predictive factors for NAL-induced diarrhea.

MATERIALS AND METHODS

Patients The present study was performed in accordance with the Declaration of Helsinki (Ninth revision: Fortaleza, Brazil, 2013) and under approval by the Nagasaki University Ethics Committee (No. 20111603). The prevalence of OIC treated with NAL was investigated in patients hospitalized at Nagasaki University Hospital (Nagasaki, Japan) between June 2017 and March 2019. In total, 242 hospitalized patients were administered NAL for the first time. Exclusion criteria are as follows: (a) patients who were transferred or were not staying in the hospital less than 3 d from the initiation of NAL; (b) patients administered NAL in the outpatient clinic or another hospital; (c) patients for whom the starting date of opioids was not identified; and (d) patients who started tube feeding after the administration of NAL.

Data Collection and Assessment This was a retrospective study. Data were obtained on age, sex, weight, primary cancer, diseases impairing blood–brain barrier function, and the opioid dose used before the administration of NAL. Diseases impairing blood–brain barrier function were defined as metastatic brain tumors, AIDS-related dementia, multiple sclerosis, and Alzheimer’s disease. Opioid doses were converted to doses equivalent to oral morphine. The conversion ratios of opioid doses and oral morphine doses were as follows: 30 mg oral morphine = 20 mg oral oxycodone = 15 mg infused oxycodone = 0.3 mg fentanyl = 100 mg tapentadol = 6 mg oral hydromorphone = 1.2 mg infused hydromorphone = 150 mg tramadol = 3.5 mg oral methadone. Blood biomedical parameters included serum creatinine, the estimated glomerular filtration rate, aspartate aminotransferase (AST), and alanine aminotransferase (ALT). The following concomitant agents were investigated: laxatives; opioids; anti-cancer agents; CYP3A4 inhibitors; CYP3A4 inducers; and P-glycoprotein inhibitors. CYP3A4 inhibitors/inducers were defined as drugs listed by the U.S. Food and Drug Administration (FDA) Drug Development and Drug Interactions: Table of Substrates, Inhibitors, and Inducers. We investigated whether patients developed diarrhea within 3 d of the administration of NAL.

Statistical Analysis Differences between 2 groups were assessed using Fisher’s exact test for categorical data and the Wilcoxon rank sum test for continuous data. Baseline characteristics were summarized with frequencies and percentages for categorical data and medians plus interquartile ranges for continuous data. Univariate logistic regression analyses were performed to evaluate the odds ratio (OR), 95% confidence intervals (CI), and p values of each potential risk factor for diarrhea from NAL. To adjust all analyses for confounders, potential confounding variables that significantly contributed to outcomes in the univariate logistic regression analysis (p < 0.1) were included in the multiple logistic regression analysis. All tests were two-sided. The level of significance was a p-value less than 0.05. Analyses were performed using JMP Pro version 15 (SAS Institute Inc., Cary, NC, U.S.A.).

RESULTS

Patient characteristics and treatment details were shown in Tables 1, 2. One hundred and sixty-three patients (67.4%) were men. In total, 40 (16.5%), 33 (13.6%), and 28 (11.6%) patients had head and neck, lung, and stomach/esophagus/small intestine cancers, respectively. Median age and weight were 66 years and 56.5 kg, respectively. The median period of opioid analgesics before the administration of NAL was 7 d. Furthermore, 20 mg was the median dose of opioid analgesics converted to oral morphine. The following drugs other than opioid analgesics were concomitantly administered: laxatives to 130 patients (53.7%), CYP3A4 inhibitors to 24 (9.9%), CYP3A4 inducers to 2 (0.8%), P-glycoprotein inhibitors to 7 (2.9%), and anticancer drugs to 107 (44.2%). Twenty-two (9.1%) patients received a moderate or strong CYP3A4 inhibitor combination, while 14 (5.8%) were using tube feeding.

The incidence of NAL-induced diarrhea was 17.8% (43 patients) (Table 3). The duration of opioid analgesics before the initiation of NAL was longer in the group with than without diarrhea (median 14 d vs. 6 d, p = 0.002). In addition, the number of patients who received the combination of CYP3A4 inhibitors (strong/moderate) and laxatives was significantly higher in the group with than without diarrhea (p = 0.011 and 0.035, respectively).

The results of the univariate logistic regression analysis

Table 1. Patient Characteristics

| Characteristic               | n = 242 |
|------------------------------|---------|
| Sex (male)                   | 163 (67.4%) |
| Age (years)                  | 66 (59–74) |
| Weight (kg)                  | 56.5 (47.1–62.5) |
| Laboratory data              |         |
| Serum creatinine (mg/dL)     | 0.81 (0.64–1.03) |
| AST (IU/L)                   | 22 (16–38) |
| ALT (IU/L)                   | 18 (12–30) |
| Estimated GFR (mL/min/1.73m²)| 69.6 (53.3–85.9) |
| Main disease                 |         |
| Head and neck cancer         | 40 (16.5%) |
| Lung cancer                  | 33 (13.6%) |
| Gastric/esophageal/small intestine cancer | 28 (11.6%) |
| Liver/biliary tract cancer   | 23 (9.5%) |
| Urinary cancer               | 20 (8.3%) |
| Gynecologic cancer           | 18 (7.4%) |
| Blood cancer                 | 18 (7.4%) |
| Colorectal cancer            | 17 (7.0%) |
| Pancreatic cancer            | 15 (6.2%) |
| Malignant soft tissue tumor  | 13 (5.4%) |
| Breast cancer                | 7 (2.9%) |
| Skin cancer                  | 2 (0.8%) |
| Cancer of unknown primary    | 2 (0.8%) |
| Others (including non-cancer)| 6 (2.5%) |

Diseases impairing blood–brain barrier function 6 (2.5%)

Category data are shown by frequencies and percentages, and continuous variables are represented by the median plus interquartile range. AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, GFR: Glomerular filtration rate.
indicated that lung cancer, the administration of opioid analgesics for 8d or longer before the initiation of NAL, the combination of laxatives, CYP3A4 inhibitors (strong/moderate), and P-glycoprotein inhibitors, and the use of tube feeding were candidate risk factors for diarrhea. The results of multiple logistic regression analyses identified the administration of opioid analgesics for 8 d or longer before the initiation of NAL (OR: 2.20, 95% CI: 1.04–4.64, \( p = 0.039 \)) and the combination of laxatives (OR: 2.22, 95% CI: 1.03–4.81, \( p = 0.042 \)) and CYP3A4 inhibitors (strong/moderate) (OR: 2.80, 95% CI: 1.02–7.67, \( p = 0.045 \)) as risk factors for diarrhea (Table 4). The frequency of NAL-induced diarrhea was calculated in patients who received opioid analgesics for 8 d or longer, laxatives, and CYP3A4 inhibitors. The incidence of NAL-induced diarrhea was 7.1, 12.8, 30.8, and 37.5% when there were 0, 1, 2, and 3 predictors, respectively (Fig. 1). Details on the combination of predictors are shown in Supplementary Table 1.

**DISCUSSION**

To the best of our knowledge, this is the first study to report the combination of CYP3A4 inhibitors or laxatives as risk

| Name of medicine | \( n = 242 \) |
|------------------|----------------|
| Opioid analgesics (regular administration) (yes) | 242 (100%) |
| Oxycodeone (p.o.) | 106 (43.8%) |
| Hydromorphone (p.o.) | 36 (14.9%) |
| Morphine (p.o.) | 35 (14.5%) |
| Tapentadol (p.o.) | 20 (8.3%) |
| Oxycodeone (i.v.) | 12 (5.0%) |
| Tramadol (p.o.) | 7 (2.9%) |
| Fentanyl (patch) | 4 (1.7%) |
| Fentanyl (i.v.) | 4 (1.7%) |
| Oxycodeone (p.o.)/morphine (p.o.) | 4 (1.7%) |
| Oxycodeone (p.o.)/tramadol (p.o.) | 3 (1.2%) |
| Tapentadol (p.o.)/tramadol (p.o.) | 3 (1.2%) |
| Codeine phosphate (p.o.) | 2 (0.8%) |
| Morphine (p.o.)/codeine phosphate (p.o.) | 2 (0.8%) |
| Morphine (p.o.)/tramadol (p.o.) | 1 (0.4%) |
| Oxycodeone (p.o.)/methadone (p.o.) | 1 (0.4%) |
| Oxycodeone (p.o.)/fentanyl (patch) | 1 (0.4%) |
| Hydromorphone (i.v.) | 1 (0.4%) |

### Dosage (oral morphine equivalent mg/d)

20 (15–40)

### Administration period before the initiation of NAL (d)

7 (2–18)

### Laxative (regular administration) (yes)

130 (53.7%)

**Categorical data are shown by frequencies and percentages, and continuous variables are represented by the median plus interquartile range.**
factors for NAL-induced diarrhea. The multivariate analysis in the present study identified the combination of laxatives or CYP3A4 inhibitors (strong/medium) in addition to the duration of opioid analgesics as novel predictors of NAL-induced diarrhea. We previously reported that eight days or longer of opioid analgesics before the initiation of NAL was identified as an independent predictor of NAL-induced diarrhea. On the other hand, 12.5% of patients administered opioid analgesics within 7 d developed NAL-induced diarrhea in the previous study. The incidence of diarrhea was 7.1% (5/70) in patients who did not have any of the predictors. The three predictors identified in the present study help to prevent NAL-induced diarrhea. The incidence of diarrhea in patients with two predictive factors was 30.8%, which was approximately four-fold higher than that in patients without risk factors. Seventy out of 79 patients had received opioid analgesics for 8 d or longer before the initiation of NAL and laxatives, and this value reflects the concomitant administration of opioid analgesics and laxatives. Since the incidence of diarrhea increase with a larger number of predictors, patients with a large number of predictors need to be more carefully observed.

NAL antagonizes the μ opioid receptor in the gastrointestinal tract and attenuates OIC. The combined use of NAL and laxatives exerted additive effects on OIC and promoted excessive defecation. A previous study reported that the discontinuation of other laxatives attenuated diarrhea in 92% of patients when diarrhea developed in those who combined NAL with other laxatives. These findings are consistent with the present results showing that the combination of laxatives is a predictor of NAL-induced diarrhea.

NAL is mainly metabolized by CYP3A4. A phase I trial on healthy individuals showed that the combination of itraconazole and fluconazole, which are strong and moderate CYP3A4 inhibitors, respectively, increased the area under

| Table 3. Comparison of Patient Characteristic in the with Diarrhea Group and without Group |
|---------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Patient characteristics         | With diarrhea (n = 43)       | Without diarrhea (n = 199)   | p-Value                     |
| Sex (male)                      | 27 (62.8%)                  | 136 (68.3%)                 | 0.479<sup>a</sup>           |
| Age (years)                     | 68 (59–76)                  | 66 (58–74)                  | 0.289<sup>a</sup>           |
| Weight (kg)                     | 56.0 (45.4–61.3)            | 56.5 (47.9–63.5)            | 0.208<sup>a</sup>           |
| Laboratory data                 |                             |                             |                             |
| Serum creatinine (mg/dL)        | 0.79 (0.64–1.16)            | 0.81 (0.64–1.00)            | 0.346<sup>a</sup>           |
| AST (IU/L)                      | 26 (18–36)                  | 22 (16–38)                  | 0.445<sup>a</sup>           |
| ALT (IU/L)                      | 20 (14–27)                  | 18 (12–31)                  | 0.506<sup>a</sup>           |
| Estimated GFR (mL/min/1.73 m²)  | 68.2 (43.1–81.7)            | 69.6 (55.0–86.5)            | 0.123<sup>a</sup>           |
| Main disease                    |                             |                             |                             |
| Head and neck cancer            | 7 (16.3%)                   | 33 (16.6%)                  | 1.000<sup>a</sup>           |
| Lung cancer                     | 2 (4.7%)                    | 31 (15.6%)                  | 0.083<sup>a</sup>           |
| Gastric/esophageal/small intestine cancer | 5 (11.6%)                   | 23 (11.6%)                  | 1.000<sup>a</sup>           |
| Liver/biliary tract cancer      | 2 (4.7%)                    | 21 (10.6%)                  | 0.388<sup>a</sup>           |
| Urinary cancer                  | 4 (9.3%)                    | 16 (8.0%)                   | 0.762<sup>a</sup>           |
| Gynecologic cancer              | 5 (11.6%)                   | 13 (6.5%)                   | 0.331<sup>a</sup>           |
| Blood cancer                    | 4 (9.3%)                    | 14 (7.0%)                   | 0.536<sup>a</sup>           |
| Colorectal cancer               | 3 (7.0%)                    | 14 (7.0%)                   | 1.000<sup>a</sup>           |
| Pancreatic cancer               | 4 (9.3%)                    | 11 (5.5%)                   | 0.314<sup>a</sup>           |
| Malignant soft tissue tumor     | 1 (2.3%)                    | 12 (6.0%)                   | 0.474<sup>a</sup>           |
| Breast cancer                   | 2 (4.7%)                    | 5 (2.5%)                    | 0.611<sup>a</sup>           |
| Skin cancer                     | 1 (2.3%)                    | 1 (0.5%)                    | 0.324<sup>a</sup>           |
| Cancer of unknown primary       | 1 (2.3%)                    | 1 (0.5%)                    | 0.324<sup>a</sup>           |
| Others (including non-cancers)  | 2 (4.7%)                    | 4 (2.0%)                    | 0.289<sup>a</sup>           |
| Diseases impairing blood–brain barrier function | 1 (2.3%)                    | 5 (2.5%)                    | 1.000<sup>a</sup>           |
| Opioid analgesics (regular administration) | 20 (15–45)                  | 23 (15–40)                  | 0.667<sup>a</sup>           |
| Administration period before the initiation of NAL (d) | 14 (6–31)                  | 6 (2–17)                    | 0.002<sup>a</sup>           |
| Administration period before the initiation of NAL (>8d) | 29 (67.4%)                  | 85 (42.7%)                  | 0.004<sup>a</sup>           |
| Laxatives (regular administration) (yes) | 31 (72.1%)                  | 99 (49.8%)                  | 0.011<sup>a</sup>           |
| CYP3A4 inhibitor                |                             |                             |                             |
| Strong/moderate/weak (yes)      | 9 (20.9%)                   | 19 (9.5%)                   | 0.061<sup>a</sup>           |
| Strong/moderate (yes)           | 8 (18.6%)                   | 14 (7.0%)                   | 0.035<sup>a</sup>           |
| CYP3A4 inducer (yes)            | 0 (0%)                      | 2 (1.0%)                    | 1.000<sup>a</sup>           |
| P-glycoprotein inhibitor (yes)  | 3 (7.0%)                    | 4 (2.0%)                    | 0.109<sup>a</sup>           |
| Anti-cancer agent (yes)         | 21 (48.8%)                  | 86 (43.2%)                  | 0.504<sup>a</sup>           |
| Tube feeding (yes)              | 5 (11.6%)                   | 9 (4.5%)                    | 0.081<sup>a</sup>           |

Categorical data are shown by frequencies and percentages, and continuous variables are represented by the median plus interquartile range. a) Fisher’s exact test, b) the Wilcoxon rank sum test. AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, GFR: Glomerular filtration rate.
the curve (AUC) by 2.91- and 1.90-fold, respectively.\textsuperscript{23} We hypothesized that the combination of CYP3A4 inhibitors contributed to increase in the incidence of diarrhea by elevating the exposure level of NAL. In a phase I study, there were no NAL-related adverse events.\textsuperscript{23} The healthy individuals were not administered opioid analgesics in the present study, so we believe that they don’t have developed withdrawal symptoms. NAL is also a substrate for P-glycoprotein. The combination of cyclosporine, a P-glycoprotein inhibitor, increased the AUC of NAL by 1.78-fold.\textsuperscript{23} However, the combination of P-glycoprotein did not correlate with NAL-induced diarrhea for the results of the multivariate analysis. In the present study, only 7 patients received the combination of P-glycoprotein (2.9%), and, thus, the detection power has been insufficient. Concomitant use with p-glycoprotein inhibitors needs to be confirmed by the accumulation of more cases.

The incidence of diarrhea in phase III clinical trials was previously reported to range between 18.3 and 40.0%.\textsuperscript{13,28} However, the incidence of diarrhea in the present study was 17.8% (43/242), which was equal to or slightly lower than that reported in clinical trials. In previous clinical trials, patients who had been receiving opioid analgesics for at least 14 d were eligible to participate. Furthermore, between 74.2 and 90% of patients had been administered laxatives before the initiation of NAL. Therefore, the patient population in clinical trials was more likely to develop diarrhea than that in the present study. Furthermore, a subgroup analysis showed that diarrhea developed in 30.7% (24/78) of patients who used opioid analgesics and laxatives for 8 d or longer, which was similar to that in phase III clinical trials\textsuperscript{13,28} (Supplementary Table 1).

The present study had several limitations. Outpatients and patients who did not have a medical record of survey contents were excluded from the present study. Furthermore, the present study was conducted at a single hospital. Therefore, there have been selection biases. In addition, this was a retrospective study. The incidence of diarrhea was investigated from medical records completed by doctors or nurses; therefore, some records have been missing. Moreover, several factors were not investigated due to the lack of medical records. The performance status, physical activity, and dietary intake may affect the incidence of diarrhea. Multicenter prospective studies are needed to resolve these limitations. Although the analysis of the therapeutic effect of NAL is also as important as any other laxative,\textsuperscript{29} we did not investigate the therapeutic

### Table 4. Logistic Regression Analysis for Incidence of Naldemedine-Induced Diarrhea

|                            | Univariate analysis | Multivariate analysis |
|-----------------------------|---------------------|-----------------------|
|                            | OR (95% CI) | p-Value | OR (95% CI) | p-Value |
| Sex (female vs. male)       | 1.28 (0.64–2.54) | 0.482 | 0.25 (0.06–1.14) | 0.073 |
| Age (per 10 years)          | 1.19 (0.91–1.60) | 0.228 | 2.20 (1.04–4.64) | 0.039 |
| Weight (per 10 kg)          | 0.83 (0.62–1.12) | 0.229 |
| Laboratory data             |                     |                       |                     |
| Serum creatinine (per 0.1 mg/dL) | 1.08 (0.99–1.03) | 0.104 |
| AST (per 10 IU/L)           | 1.00 (0.92–1.06) | 0.925 |
| ALT (per 10 IU/L)           | 1.00 (0.87–1.11) | 0.974 |
| Estimated GFR (per 10 mL/min/1.73 m²) | 0.90 (0.79–1.03) | 0.124 |
| Main disease                |                     |                       |                     |
| Head and neck cancer        | 0.98 (0.40–2.39) | 0.961 |
| Lung cancer                 | 0.26 (0.06–1.15) | 0.076 |
| Gastric/esophageal/small intestine cancer | 1.01 (0.32–2.63) | 0.990 |
| Liver/biliary tract cancer  | 0.41 (0.07–1.49) | 0.196 |
| Urinary cancer              | 1.17 (0.37–3.70) | 0.785 |
| Gynecologic cancer          | 1.88 (0.63–5.59) | 0.255 |
| Blood cancer                | 1.36 (0.42–4.34) | 0.609 |
| Colorectal cancer           | 0.99 (0.22–3.21) | 0.989 |
| Pancreatic cancer           | 1.75 (0.53–5.79) | 0.357 |
| Malignant soft tissue tumor | 0.37 (0.02–1.96) | 0.283 |
| Breast cancer               | 1.89 (0.35–10.10) | 0.455 |
| Skin cancer                 | 4.71 (0.29–76.89) | 0.276 |
| Cancer of unknown primary   | 4.71 (0.29–76.89) | 0.276 |
| Others (including non-cancers) | 2.38 (0.42–13.42) | 0.327 |
| Diseases impairing blood–brain barrier function (yes vs. no) | 0.92 (0.11–8.11) | 0.943 |
| Opioid analgesics (regular administration) |                     |                       |                     |
| Dosage (per oral morphine equivalent 10 mg/d) | 0.96 (0.84–1.02) | 0.494 |
| Administration period before the initiation of NAL (>8d vs. 1–7d) | 2.78 (1.38–5.58) | 0.004 |
| Laxatives (regular administration) (yes vs. no) | 2.61 (1.27–5.37) | 0.009 |
| CYP3A4 inhibitor (Strong/Medium vs. Weak/Nothing) | 3.02 (1.18–7.74) | 0.021 |
| CYP3A4 inducer (yes vs. no) |                     | 2.80 (1.02–7.67) | 0.045 |
| P-glycoprotein inhibitor (yes vs. no) | 3.66 (0.79–16.97) | 0.098 |
| Anti-cancer agent (yes vs. no) | 1.25 (0.65–2.43) | 0.501 |
| Tube feeding (yes vs. no)   | 2.78 (0.88–8.75) | 0.081 |

AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, GFR: Glomerular filtration rate.
Diarrhea and CYP3A4 Inhibitors Are Predictors of Naldemedine-Induced Bowel Dysfunction. The development of diarrhea needs to be considered prior to the administration of NAL to patients with these predictors. In addition, diarrhea may be avoided by using opioid analgesics within 7 d of the initiation of NAL and, if possible, discontinuing or changing the combination of moderate or strong CYP3A4 inhibitors. The present results provide useful basic information for the proper use of NAL; however, further studies are warranted.

Acknowledgments We thank the patients and all medical staff at Nagasaki University Hospital who contributed to this study.

Conflict of Interest The authors declare no conflict of interest.

Supplementary Materials The online version of this article contains supplementary materials.

REFERENCES

1) McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control, 11(Suppl. 1), 3–9 (2004).

2) Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain, 112, 372–380 (2004).

3) Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a U.S. and European Patient Survey (PROBE 1). Pain Med., 10, 35–42 (2009).

4) Ishihara M, Ikesue H, Matsunaga H, Suenaru K, Kitachi K, Suzuki K, Oishi R, Seno T, Araki H, Itoh Y. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin. J. Pain, 28, 373–381 (2012).

5) Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology, 150, 1393–1407 (2016).

6) Coyne KS, Margolis MK, Yeomans K, King FR, Chavoshi S, Payne KA, LoCasale RJ. Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time. Pain Med., 16, 1551–1565 (2015).

7) Abramowicz L, Beziani N, Latreze L, Giardina V, Caussé C, Chuberre B, Aillaert FA, Perrot S. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J. Med. Econ., 16, 1423–1433 (2013).

8) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol., 13, e58–e68 (2012).

9) Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgathe C, Scotté F, Ripamonti CI. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann. Oncol., 29 (Suppl. 4), iv111–iv125 (2018).

10) Swarm RA, Paice JA, Anghelescu DL, et al. Adult cancer pain, Version 3.2019, NCCN Clinical Practice Guidelines in oncology. J. Natl. Compr. Canc. Netw., 17, 977–1007 (2019).

11) Japan Society for Palliative Medicine. Clinical guidelines for cancer pain management (third edition). KANEHARA & Co., Ltd., Tokyo, Japan, pp. 143–145 (2020).

12) Nishie K, Yamamoto S, Yamaga T, Horigome N, Hanaoka M. Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: systematic review and meta-analysis. J. Gastroenterol. Hepatol., 34, 818–829 (2019).

13) Katakami N, Harada T, Murata I, Shimonoki K, Tsutsui M, Yoko-ta T, Arai M, Tada Y, Narabayashi M, Boku N. Randomized Phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J. Clin. Oncol., 35, 3859–3866 (2017).

14) Yuan CS, Fos JF, O’Connor M, Osinski J, Karrison T, Moss J, Roizen MF. Melanin-polyethylene for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA, 327, 362–372 (2000).

15) Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidov J, Pierce A, Mortensen E, Kleudges C, Carter E. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain, 137, 428–440 (2008).

16) Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med., 370, 2387–2396 (2014).

17) Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J. Pain Symptom Manage., 23, 48–53 (2002).

18) Ouyang R, Li Z, Huang S, Liu J, Huang J. Efficacy and safety of peripherally acting mu-opioid receptor antagonists for the treatment
of opioid-induced constipation: a bayesian network meta-analysis. Pain Med., 21, 3224–3232 (2020).
19) Wild J, Yamada T, Arjona Ferreira JC, Hale M. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials. Pain, 160, 2358–2364 (2019).
20) Hashizume J, Ryu E, Nose S, Miyanaga K, Kishikawa R, Nakamura T, Muro T, Kodama Y, Yamashita H, Ishii K, Sasaki H. Predictors for diarrhea after administration of naldemedine: analysis focusing on the administration period of opioid analgesics before the start of naldemedine. Palliative Care Research, 15, 101–109 (2020).
21) Takagi Y, Osawa G, Kato Y, Ikezawa E, Kobayashi C, Aruga E. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study. BMC Gastroenterol., 20, 25 (2020).
22) Okamoto A, Ikemura K, Mizutani E, Iwamoto T, Okuda M. Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study. J. Pharm. Health Care Sci., 7, 3 (2021).
23) Fukumura K, Kawaguchi N, Ishibashi T, Kubota R, Tada Y, Ogura E. Clinical drug–drug interaction studies to evaluate the effects of a P-glycoprotein inhibitor, CYP3A inhibitors, and a CYP3A inducer on the pharmacokinetics of naldemedine in healthy subjects. Clin. Drug Investig., 40, 529–540 (2020).
24) Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, Suzuki Y, Narabayashi M, Boku N. Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. J. Clin. Oncol., 35, 1921–1928 (2017).
25) Webster LR, Yamada T, Arjona Ferreira JC. A Phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med., 18, 2350–2360 (2017).
26) Shionogi Pharma Co., Ltd., Simploc® Tablets 0.2 mg Interview Form (4th edition) p. 73, Revised in July 2020.
27) U.S. Food and Drug Administration. “Drug development and drug interactions: table of substrates, inhibitors and inducers.”: <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers>, accessed 23 November, 2020.
28) Saito Y, Yokota T, Arai M, Tada Y, Sumitani M. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies. J. Pain Res., 12, 127–138 (2018).
29) Sada H, Kajizono M, Ushio S, Esumi S, Kitamura Y, Sendo T. The efficacy and safety of lubiprostone for constipation in cancer patients compared with non-cancer patients: a retrospective cohort study. Biol. Pharm. Bull., 43, 1699–1706 (2020).